NLS Pharmaceutics
NLSP
NLSP
5 hedge funds and large institutions have $3.44M invested in NLS Pharmaceutics in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
| 1 |
JGC
1
J. Goldman & Co
New York
|
$0 |
| 2 |
AAA
2
Affinity Asset Advisors
New York
|
$0 |
| 3 |
3
Renaissance Technologies
New York
|
$7K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $3.39M | – | – | – |
|
2
Wells Fargo
San Francisco,
California
| $33.4K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $8.47K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $7K | -$4.66K | -211 | -40% |
|
5
Bank of America
Charlotte,
North Carolina
| $53 | – | – | – |
|
|
JGC
6
J. Goldman & Co
New York
| – | -$178K | -6,365 | Closed |
|
|
AAA
7
Affinity Asset Advisors
New York
| – | -$140K | -5,011 | Closed |
|